Kamber Niklaus, Davis Timothy M E
University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, Fremantle, WA 6959, Australia.
IDrugs. 2005 Nov;8(11):927-35.
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
阿斯利康制药公司正在研发替格列扎，一种口服双过氧化物酶体增殖物激活受体α/γ激动剂，用于潜在改善2型糖尿病患者的血脂异常和血糖控制。
Zotero 插件